Want to see IN:CAPLIPOINT full AI Analyst Report?

Caplin Point Laboratories Limited (CAPLIPOINT) Price & Analysis

4 Followers

CAPLIPOINT Stock Chart & Stats

₹1845.95

-₹76.70(-2.97%)

At close: Jan 09 4:00 PM EST

₹1845.95

-₹76.70(-2.97%)

Day’s Range― - ―

52-Week Range₹1,502.45 - ₹2,680.00

Previous CloseN/A

Volume128.91K

Average Volume (3M)3.75K

Market Cap

₹192.72B

Enterprise Value₹172.14B

Total Cash (Recent Filing)₹10.07B

Total Debt (Recent Filing)₹46.10M

Price to Earnings (P/E)30.1

Beta1.35

Next Earnings

Aug 12, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.31%

Share Statistics

EPS (TTM)84.36

Shares Outstanding76,011,696

10 Day Avg. Volume2,866

30 Day Avg. Volume3,752

Financial Highlights & Ratios

PEG Ratio0.91

Price to Book (P/B)3.19

Price to Sales (P/S)5.23

P/FCF Ratio33.98

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)91.6

Revenue Forecast (FY)₹23.73B

Bulls Say, Bears Say

Bulls Say

Consistent Revenue GrowthSustained mid‑single to double‑digit revenue growth demonstrates durable end‑market demand and successful commercial execution. Over 2–6 months this underpins scale advantages, supports reinvestment in complex dosage forms and helps absorb fixed costs, reinforcing long‑term earnings power.

Strong And Sustainable MarginsHigh gross and net margins indicate pricing power and a favorable product mix (injectables, ophthalmics, finished formulations). Such structural profitability supports cash generation, funds R&D/manufacturing investments, and creates a cushion against cyclical cost swings over the medium term.

Conservative Balance Sheet And Improving Cash FlowVery low leverage plus rising operating cash flow gives financial flexibility for capex, product approvals, or bolt‑on M&A without straining liquidity. This durability reduces solvency risk, lowers financing costs, and supports steady investment in manufacturing and compliance.

Bears Say

Recent Margin Volatility And Potential CompressionSlower gross profit growth versus revenue signals margin pressure that could persist if product mix shifts or input costs rise. Persistent compression would erode cash flow and ROE, reducing capacity to fund investments and weakening the company’s long‑term profitability profile.

Uneven Free Cash Flow ConversionInconsistent FCF relative to earnings—including sharp dips—indicates working capital or capex volatility. Over months this can constrain dividends, investments, or debt reduction plans and raises execution risk when scaling exports or funding regulatory compliance.

Exposure To Regulated And Semi-regulated MarketsServing varied regulatory regimes increases compliance, inspection and approval risk and can raise costs or cause market access delays. Structurally higher compliance burden can slow launches, raise capex for quality systems, and amplify downside from regulatory actions.

Caplin Point Laboratories Limited News

Caplin Steriles Wins USFDA Nod for Calcium Gluconate Injection, Expands U.S. Injectables Push

Caplin Point Laboratories Limited ( ($IN:CAPLIPOINT) ) just unveiled an update. Caplin Steriles, the sterile injectables arm of...

2M ago

Caplin Point Buys $473 Million Portfolio of US-Approved Injectable and Ophthalmic ANDAs

Caplin Point Laboratories Limited ( ($IN:CAPLIPOINT) ) has shared an update. Caplin Point Laboratories, through its subsidiaries Caplin...

6M ago

Caplin Steriles Secures USFDA Approval for Acetaminophen Injection

The latest update is out from Caplin Point Laboratories Limited ( ($IN:CAPLIPOINT) ). Caplin Steriles Limited, a subsidiary...

7M ago

Caplin Point Laboratories Announces Financial Results and New Appointments

An announcement from Caplin Point Laboratories Limited ( ($IN:CAPLIPOINT) ) is now available. Caplin Point Laboratories Limited announced...

8M ago

Caplin Point Laboratories Announces Trading Window Closure

Caplin Point Laboratories Limited ( ($IN:CAPLIPOINT) ) just unveiled an announcement. Caplin Point Laboratories Limited announced the closure...

9M ago

Caplin Point Laboratories Sets Record Date for Dividend Ahead of AGM

Caplin Point Laboratories Limited ( ($IN:CAPLIPOINT) ) has provided an announcement. Caplin Point Laboratories Limited has announced the...

11M ago

CAPLIPOINT FAQ

What was Caplin Point Laboratories Limited’s price range in the past 12 months?

Caplin Point Laboratories Limited lowest stock price was ₹1502.45 and its highest was ₹2680.00 in the past 12 months.

What is Caplin Point Laboratories Limited’s market cap?

Caplin Point Laboratories Limited’s market cap is ₹192.72B.

When is Caplin Point Laboratories Limited’s upcoming earnings report date?

Caplin Point Laboratories Limited’s upcoming earnings report date is Aug 12, 2026 which is in 38 days.

How were Caplin Point Laboratories Limited’s earnings last quarter?

Caplin Point Laboratories Limited released its earnings results on May 14, 2026. The company reported ₹22.9 earnings per share for the quarter, beating the consensus estimate of N/A by ₹22.9.

Is Caplin Point Laboratories Limited overvalued?

According to Wall Street analysts Caplin Point Laboratories Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Caplin Point Laboratories Limited pay dividends?

Caplin Point Laboratories Limited pays a Quarterly dividend of ₹4 which represents an annual dividend yield of 0.31%. See more information on Caplin Point Laboratories Limited dividends here

What is Caplin Point Laboratories Limited’s EPS estimate?

Caplin Point Laboratories Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Caplin Point Laboratories Limited have?

Caplin Point Laboratories Limited has 76,011,696 shares outstanding.

What happened to Caplin Point Laboratories Limited’s price movement after its last earnings report?

Caplin Point Laboratories Limited reported an EPS of ₹22.9 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 9.769%.

Which hedge fund is a major shareholder of Caplin Point Laboratories Limited?

Currently, no hedge funds are holding shares in IN:CAPLIPOINT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Caplin Point Laboratories Limited

Caplin Point Laboratories Limited is a pharmaceutical firm actively involved in the development, manufacture, marketing, and export of both generic medications and proprietary branded products, primarily operating within India. Their extensive product portfolio encompasses a broad spectrum of pharmaceutical dosage forms, including various types of injections (liquid, lyophilized, IV infusions, powder for injection), oral preparations (tablets, liquid orals, capsules, softgel capsules, dry syrups), specialized applications (ophthalmic products, suppositories and ovules), and topical treatments (topicals, dermo cosmetics, inhalers). Beyond manufacturing, the company also manages an e-commerce platform named QueTenX. Established in 1990, Caplin Point Laboratories maintains its headquarters in Chennai, India.